Group 1: U.S. Stock Market Overview - U.S. stock futures were higher, with Dow futures gaining over 100 points on Monday [1] Group 2: Inventiva ADR Performance - Inventiva reported a loss of $(1.84) per share, significantly worse than the analyst consensus estimate of a loss of 41 cents per share [1] - The company’s quarterly sales were $5.050 million, missing the analyst consensus estimate of $5.310 million [1] - Inventiva shares fell 5.5% to $5.72 in pre-market trading [1] Group 3: Other Stocks in Pre-Market Trading - MoonLake Immunotherapeutics saw a significant decline of 86.3% to $8.50 in pre-market trading [4] - Cellectis SA declined 10.4% to $3.01 in pre-market trading [4] - Quantum-Si Inc fell 10.1% to $1.34 in pre-market trading after filing for a mixed shelf of up to $300 million [4] - Penguin Solutions Inc dropped 8.4% to $24.00 in pre-market trading [4] - Lithium Americas Corp declined 5.4% to $5.99 in pre-market trading after a 14% dip on Monday [4] - Platinum Analytics Cayman Ltd fell 5.3% to $16.20 in pre-market trading after a 44% jump on Monday [4] - Novo Nordisk A/S decreased by 2.9% to $54.01 in pre-market trading [4] - Lexicon Pharmaceuticals Inc declined 2.9% to $1.36 in pre-market trading, with an update on additional data submission to the U.S. FDA regarding Zynquista® in Type 1 Diabetes [4]

Core Viewpoint - Inventiva is a clinical-stage biopharmaceutical company focused on developing oral therapies for metabolic dysfunction-associated steatohepatitis (MASH) and is advancing its Phase 3 clinical trial for MASH, which is crucial for its mission to provide therapeutic solutions for patients [1] Financial Performance - On September 25, 2025, Inventiva reported an earnings per share (EPS) of -$0.64, which was below the estimated EPS of -$0.41, while generating revenue of approximately $5.24 million, slightly surpassing estimates [2][6] - The company has secured a €116 million tranche of structured financing, enhancing its financial position with cash and cash equivalents totaling €146.7 million as of June 30, 2025, ensuring a cash runway until the end of the third quarter of 2026 [3][6] Financial Metrics - Inventiva's financial metrics indicate a challenging environment, with a price-to-earnings (P/E) ratio of approximately -1.46, reflecting negative earnings, and a price-to-sales ratio of about 33.51, indicating that investors are paying $33.51 for every dollar of sales [4][6] - The enterprise value to sales ratio is approximately 28.92, showing the company's valuation relative to its sales [4] - The debt-to-equity ratio is about -0.51, indicating more liabilities than equity, and the current ratio of approximately 0.92 suggests potential difficulty in covering short-term liabilities with short-term assets [5][6]

Core Insights - Inventiva has made significant progress in its clinical program and financial position during the first half of 2025, particularly in its Phase 3 clinical trial for MASH [2][23] - The company reported revenues of €4.5 million for the first half of 2025, a substantial increase from €41,000 in the same period of 2024 [4][11] - A net loss of €175.9 million was recorded for the first half of 2025, compared to a net loss of €49.0 million in the first half of 2024 [11][12] Financial Performance - Revenues for the first half of 2025 were primarily driven by a €10 million milestone payment from Chia Tai Tianqing Pharmaceutical Group and €5 million in credit notes under a license agreement [5] - Other income decreased to €1.2 million in the first half of 2025 from €2.7 million in the same period of 2024, attributed to changes in R&D tax credit eligibility [6] - Research and development expenses were €44.9 million, down 4% from €46.8 million in the first half of 2024, reflecting a decrease in costs related to discontinued preclinical programs [7] Cash Position - As of June 30, 2025, cash and cash equivalents totaled €146.7 million, including €24.6 million in short-term deposits, with a cash runway projected until the end of Q3 2026 [8][16] - The company generated €104.8 million from financing activities in the first half of 2025, primarily from the second tranche of structured financing [14] Corporate Developments - A leadership transition occurred with the appointment of Jason Campagna as President of R&D and Chief Medical Officer [18] - The company received authorization for a workforce reduction plan, which began implementation in May 2025 [18] - The completion of enrollment for the pivotal Phase 3 clinical trial, NATiV3, was announced on April 1, 2025 [18] Future Outlook - Topline results from the NATiV3 trial are expected in the second half of 2026 [20] - The company plans to raise additional funds for long-term objectives, including potential public offerings or strategic partnerships [17]

Group 1 - Inventiva S.A. is set to release its earnings results for the first half of the year on September 29, with analysts expecting a loss of 41 cents per share [1] - The company projects quarterly revenue of $5.31 million [1] - Shares of Inventiva rose by 0.7% to close at $6.05 on the preceding Friday [1] Group 2 - HC Wainwright & Co. analyst Ananda Ghosh has a Buy rating with a price target of $20 [7] - Guggenheim analyst Etzer Darout maintained a Buy rating and increased the price target from $9 to $13 [7] - Piper Sandler analyst Yasmeen Rahimi initiated coverage with an Overweight rating and a price target of $26 [7] - Stifel analyst Annabel Samimy maintained a Buy rating but reduced the price target from $20 to $17 [7] - UBS analyst Eliana Merle initiated coverage with a Neutral rating and a price target of $3 [7]

Group 1 - Inventiva S.A. is set to release its earnings results for the first half of the year on September 29, with analysts expecting a loss of 41 cents per share and projected quarterly revenue of $5.31 million [1] - The company will host an Analyst and Investor Event on October 8 [1] - Shares of Inventiva increased by 0.7% to close at $6.05 on the preceding Friday [1] Group 2 - HC Wainwright & Co. analyst Ananda Ghosh has a Buy rating on the stock with a price target of $20, initiated on September 3, 2025 [7] - Guggenheim analyst Etzer Darout maintained a Buy rating and raised the price target from $9 to $13 on September 2, 2025 [7] - Piper Sandler analyst Yasmeen Rahimi initiated coverage with an Overweight rating and a price target of $26 on August 27, 2025 [7] - Stifel analyst Annabel Samimy maintained a Buy rating but reduced the price target from $20 to $17 on November 22, 2024 [7] - UBS analyst Eliana Merle initiated coverage with a Neutral rating and a price target of $3 on November 12, 2024 [7]

Core Viewpoint - Inventiva S.A. (IVA) has shown a downtrend recently, losing 5.4% over the past four weeks, but a hammer chart pattern suggests a potential trend reversal as buying interest may be emerging [1][2]. Technical Analysis - The hammer chart pattern indicates a possible bottom formation, suggesting that selling pressure may be exhausting and that bulls could be gaining control [2][5]. - A hammer pattern forms when there is a small candle body with a long lower wick, indicating that the stock opened lower, made a new low, but closed near or above the opening price, signaling potential support [4][5]. - This pattern can occur across various timeframes and is utilized by both short-term and long-term investors [5]. Fundamental Analysis - There has been a positive trend in earnings estimate revisions for IVA, which is a bullish indicator suggesting potential price appreciation [7]. - The consensus EPS estimate for the current year has increased by 4.4% over the last 30 days, indicating that analysts expect better earnings than previously predicted [8]. - IVA holds a Zacks Rank of 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks, which typically outperform the market [9][10].

Core Viewpoint - Inventiva is hosting an analyst and investor event to provide a strategic update ahead of the anticipated Phase 3 topline results for lanifibranor, its lead asset for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) [1] Company Overview - Inventiva is a clinical-stage biopharmaceutical company focused on developing oral small molecule therapies for MASH [3] - The company is evaluating lanifibranor, a novel pan-PPAR agonist, in the pivotal Phase 3 NATiV3 clinical trial for adult patients with MASH, a progressive chronic liver disease [3] Event Details - The event will take place on October 8, 2025, from 11:30 am to 2:00 pm ET in New York City, with a live webcast available [1] - The program will include presentations from Inventiva's leadership and insights from key opinion leaders in the MASH field, along with a patient representative [2][5] Key Topics of Discussion - An update on lanifibranor ahead of the anticipated Phase 3 NATiV3 topline results expected in the second half of 2026 [5] - A deep dive into lanifibranor's mechanism of action and clinical evidence, including findings from the Phase 2b trial [6] - Discussion on the design and objectives of the ongoing Phase 3 study, including patient baseline characteristics [6] - Insights from renowned experts in the field, including Dr. Nezam Afdhal, Dr. William Alazawi, Henry E. Chang, and Dr. Arun Sanyal [6]

Group 1 - U.S. stock futures showed mixed results, with Dow futures declining approximately 100 points [1] - RH reported second-quarter earnings of $2.93 per share, missing the analyst estimate of $3.20, and quarterly revenue of $899.15 million, which fell short of the Street estimate of $904.64 million [1] - RH shares dropped 11.5% to $201.98 in pre-market trading following the earnings report [2] Group 2 - Rent the Runway, Inc. saw a significant decline of 27.1% to $5.75 in pre-market trading after reporting disappointing second-quarter EPS results [4] - Frequency Electronics Inc experienced an 11% drop to $30.56 in pre-market trading due to downbeat financial results for its first quarter [4] - Zhengye Biotechnology Holding Ltd fell 9.3% to $8.35 in pre-market trading after a previous decline of 11% [4] - Inventiva S.A. dipped 8.5% to $5.28 in pre-market trading after a 4% gain the previous day [4] - Kindly MD, Inc. declined 7.7% to $3.64 in pre-market trading [4] - Tronox Holdings plc fell 5.7% to $4.71 in pre-market trading, with Mizuho analyst John Roberts downgrading the stock from Neutral to Underperform and setting a $4 price target [4] - ABIVAX Société Anonyme decreased by 4.7% to $81.94 in pre-market trading [4] - Certara, Inc. fell 4.3% to $10.45 in pre-market trading [4]

Company Overview - Inventiva is a clinical-stage biopharmaceutical company focused on developing oral therapies for metabolic dysfunction-associated steatohepatitis (MASH) and other diseases with significant unmet medical needs [2][4] - The company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in the NATiV3 pivotal Phase 3 clinical trial for treating adult patients with MASH, a common and progressive chronic liver disease [2] Upcoming Investor Events - The company will participate in several upcoming investor events, including: - H.C. Wainwright 27th Annual Global Investment Conference on September 9, 2025, at 3:00 PM EDT in New York, NY [1] - 8th Edition of the Lyon Pôle Bourse Forum on September 23, 2025, in Lyon, France [1] - KBC Life Sciences Conference on September 25, 2025, at 5:00 AM EDT in Brussels, Belgium [2] - Stifel 2025 Virtual Cardiometabolic Forum on September 30, 2025, at 9:30 AM EDT, virtually [2] - European MIDCAP Event 2025 from September 30 to October 1, 2025, in Paris, France [2]

Core Insights - Inventiva is a clinical-stage biopharmaceutical company focused on developing oral therapies for metabolic dysfunction-associated steatohepatitis (MASH) [1][3] - The company will participate in the Canaccord Genuity 45th Annual Growth Conference, highlighting updates on lanifibranor and the Phase III NATiV3 trial [2][3] Company Overview - Inventiva is listed on Euronext Paris and NASDAQ, focusing on oral small molecule therapies for MASH and other diseases with significant unmet medical needs [3][4] - The company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in a pivotal Phase 3 clinical trial for adult patients with MASH [3]